Skip to Content

News & Events

For media inquiries email [email protected]

Company news

October 17, 2025 Press Release

Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001

September 3, 2025 Press Release

Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer

May 30, 2025 Press Release

Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings

Publications and presentations

October 17, 2025 ESMO Congress

A Phase 1/2 trial of FOG-001, a first-in-class direct β-catenin-TCF4 inhibitor: safety and preliminary antitumor activity in patients with desmoid tumors

June 2, 2025 ASCO Annual Meeting

A Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors

May 2, 2025 AACR Annual Meeting

Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon) degraders enables pharmacological validation in ERG-fusion prostate cancer models

Recent highlights

May 2, 2025 Podcast

“Therapeutic Momentum” Interview with Mathai Mammen

Parabilis CEO Mathai Mammen joined Karen Akinsanya, head of therapeutics R&D at Schrodinger, on the Therapeutic Momentum podcast for a wide-ranging discussion of science, leadership, purpose — and the very human motivations that fuel innovation.

Upcoming events

October 22, 2025 Boston

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics